slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Porphyria (Erythropoietic Protoporphyri) Market Size, Share, Treatment, Symptom and Pipeline Review, H1 2016 PowerPoint Presentation
Download Presentation
Porphyria (Erythropoietic Protoporphyri) Market Size, Share, Treatment, Symptom and Pipeline Review, H1 2016

Loading in 2 Seconds...

  share
play fullscreen
1 / 4
Download Presentation

Porphyria (Erythropoietic Protoporphyri) Market Size, Share, Treatment, Symptom and Pipeline Review, H1 2016 - PowerPoint PPT Presentation

Amber123
93 Views
Download Presentation

Porphyria (Erythropoietic Protoporphyri) Market Size, Share, Treatment, Symptom and Pipeline Review, H1 2016

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Hexa Reports Market Research Reports and Insightful Company Profiles Porphyria (Erythropoietic Protoporphyri) Market Size, Share, Treatment, Symptoms, Global Insights, Trends and Growth, Causes, Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016', provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued projects. Browse Detail Report With TOC @ http://www.hexareports.com/report/porphyria-erythropoietic- protoporphyri-pipeline-review-h1-2016/details Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest

  2. Hexa Reports Market Research Reports and Insightful Company Profiles set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Porphyria (Erythropoietic Protoporphyri) - The report reviews pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre- registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Porphyria (Erythropoietic Protoporphyri) therapeutics and enlists all their major and minor projects - The report assesses Porphyria (Erythropoietic Protoporphyri) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter- strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Porphyria (Erythropoietic Protoporphyri) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  3. Hexa Reports Market Research Reports and Insightful Company Profiles - Devise corrective measures for pipeline projects by understanding Porphyria (Erythropoietic Protoporphyri) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Request A Sample copy of This Report @ http://www.hexareports.com/sample/135404 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Porphyria (Erythropoietic Protoporphyri) Overview 7 Therapeutics Development 8 Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Overview 8 Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis 9 Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Development by Companies 10 Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Investigation by Universities/Institutes 11 Porphyria (Erythropoietic Protoporphyri) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Porphyria (Erythropoietic Protoporphyri) - Products under Development by Companies 15 Porphyria (Erythropoietic Protoporphyri) - Products under Investigation by Universities/Institutes 16 Porphyria (Erythropoietic Protoporphyri) - Companies Involved in Therapeutics Development 17 Alnylam Pharmaceuticals, Inc. 17 Clinuvel Pharmaceuticals Limited 18 Digna Biotech, S.L. 19 UniQure N.V. 20 Porphyria (Erythropoietic Protoporphyri) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 afamelanotide - Drug Profile 30 Product Description 30

  4. Hexa Reports Market Research Reports and Insightful Company Profiles Mechanism of Action 30 R&D Progress 30 Browse Full Report @ http://www.hexareports.com/report/porphyria-erythropoietic-protoporphyri- pipeline-review-h1-2016/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Visit Our Blogs: http://hexareports.blogspot.in